SEC
KPTI icon

Seven Eight Capital’s Karyopharm Therapeutics KPTI Stock Holding History

Seven Eight Capital’s Portfolio KPTI Stock Details KPTI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-3,107
Closed -$721K – 647
2021
Q1 		$721K Hold
3,107
– – 0.17% 209
2020
Q4 		$721K Sell
3,107
-2,066
-40% -$479K 0.16% 212
2020
Q3 		$1.13M Buy
+5,173
New +$1.27M 0.24% 134
2020
Q1 		– Sell
-1,620
Closed -$466K – 591
2019
Q4 		$466K Buy
+1,620
New +$351K 0.02% 538

Other funds holding KPTI

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
DMPV
Delphi Management Partners VIII San Mateo, California $138M AUM 56.74% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $9.73B AUM 55.65% 1-Year Est. Return
RHJA
Rice Hall James & Associates San Diego, California $1.8B AUM 36.16% 1-Year Est. Return

Seven Eight Capital's KPTI Position: Q2 2021 in Review

Seven Eight Capital sold out of Karyopharm Therapeutics (KPTI) in Q2 2021, closing a stake of 3,107 shares — an estimated $721K sold.

Seven Eight Capital first reported a position in KPTI in Q4 2019 and held it in 4 quarters. The position peaked at $1.13M in Q3 2020. 153 funds tracked by Wall St. Rank hold KPTI as of Q2 2021.

  • Seven Eight Capital reported no remaining Karyopharm Therapeutics position as of Q2 2021 after selling out during the quarter.
  • Seven Eight Capital sold 3,107 Karyopharm Therapeutics shares in Q2 2021, an estimated $721K.
  • Seven Eight Capital first reported a position in Karyopharm Therapeutics in Q4 2019 and held it in 4 quarters.
  • Seven Eight Capital's Karyopharm Therapeutics position peaked at $1.13M in Q3 2020.
  • 153 funds tracked by Wall St. Rank held Karyopharm Therapeutics as of Q2 2021.

Based on Seven Eight Capital's 13F filing for Q2 2021, filed 13 Aug 2021.